Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017

Publisher Name :
Date: 16-May-2017
No. of pages: 35
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).

  • The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Organophosphate and Carbamate Poisoning - Overview
Organophosphate and Carbamate Poisoning - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Organophosphate and Carbamate Poisoning - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
Countervail Corp
Hager Biosciences LLC
Organophosphate and Carbamate Poisoning - Drug Profiles
AM-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galantamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PlantVax-1502-H-N - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate BuChE for Carbamate and Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Organophosphate and Carbamate Poisoning - Dormant Projects
Organophosphate and Carbamate Poisoning - Discontinued Products
Organophosphate and Carbamate Poisoning - Product Development Milestones
Featured News & Press Releases
Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corp, H1 2017
Organophosphate and Carbamate Poisoning - Pipeline by Hager Biosciences LLC, H1 2017
Organophosphate and Carbamate Poisoning - Dormant Projects, H1 2017
Organophosphate and Carbamate Poisoning - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global Peptide Therapeutics Market Professional Survey Report 2018
    Published: 21-Feb-2018        Price: US 3500 Onwards        Pages: 100
    This report studies Peptide Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Pfizer - Eli Lilly and Company - Bachem Holding - Amgen ......
  • Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 2000 Onwards        Pages: 113
    Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2018, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells......
  • Liver Cirrhosis - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 2000 Onwards        Pages: 88
    Liver Cirrhosis - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2018, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which ......
  • United States Liver Disease Treatment Market Report 2018
    Published: 20-Feb-2018        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Liver Disease Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth ......
  • China Lupus Therapeutic Market Research Report 2018
    Published: 19-Feb-2018        Price: US 3400 Onwards        Pages: 114
    The global Lupus Therapeutic market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%. This report studies the Lupus Therapeutic development status and future trend in China, focuses on top players in China, also splits Lupus Ther......
  • Global Human Microbiome Therapeutics Market Professional Survey Report 2018
    Published: 13-Feb-2018        Price: US 3500 Onwards        Pages: 104
    This report studies Human Microbiome Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - ENTEROME Bioscience - Rebiotix - Seres Therapeutics - ......
  • Japan Proton Therapy Market Research Report 2018
    Published: 13-Feb-2018        Price: US 1100 Onwards        Pages: 110
    The report titled “Japan Proton Therapy Market Research Report 2018” examines the market dynamics, competitive landscape and discusses major trends.  The report offers the most up-to-date industry data on the actual and potential market situation, and future outlook for proton therapy in Japan. The research includes historic data from 2012 to 2017 and forecasts until 2025. Long–term Growth Projection: Hitachi and Mitsubishi Electr......
  • 2015-2023 World Infantile Spasms Therapeutics Market Research Report by Product Type, End-User / Application and Regions / Countries
    Published: 12-Feb-2018        Price: US 2800 Onwards        Pages: 135
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc)......
  • China Globoid Cell Leukodystrophy Treatment Market Research Report 2018
    Published: 12-Feb-2018        Price: US 3400 Onwards        Pages: 96
    The global Globoid Cell Leukodystrophy Treatment market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%. This report studies the Globoid Cell Leukodystrophy Treatment development status and future trend in China, focuses on top ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs